Best Radiation Therapy for Sarcomas doctors in Israel: TOP 4 doctors

Prof. Merimsky leads the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center – a pioneer in sarcoma treatment with over 41 years of experience of focused expertise.

• Fellowship-trained at Institut Gustave Roussy in Paris – Europe's leading sarcoma center
• ESMO Faculty member for sarcoma – helps shape international treatment guidelines
• Published extensively on sarcoma therapies and outcomes
• Combines radiation oncology with systemic treatment approaches

Dr. Dror Levin specializes in pediatric sarcoma treatment at Sourasky Medical Center – one of Israel's leading hospitals for childhood cancers.

• Director of pediatric hematology oncology at Sourasky
• Trained at Rizzoli Orthopaedic Institute – a world leader in sarcoma care
• Coordinates sarcoma treatment with orthopedic oncology teams
• Member of Israel's pediatric hemato-oncology association (ISPHO)

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.